A recent investor presentation from Collagenex gives some hints as to how Collagenex will price COL-118.

Collagenex believe that their anti erythema product used for  2-4 months of treatment at $150 a month leads to a $330-660 million market. $150 a month for COL-118 treatment sounds like a lot. One wonders how much the suggested $150 a month will translate to at the pharmacy counter.

So this presentation means we can expect COL-188 prescriptions to be expensive. It seems unlikely to me that sufferers will be able to cease treatment after just a couple of months. We need to see more published information about whether any lasting benefit is seen after 4 months usage.

It takes a reasonable sized pharmaceutical company to get rosacea treatments tested and approved – and naturally the company’s shareholders will want a return on their investment.

One final thought. I wonder what Collagenex are going to call COL-118 when they are ready to bring it to the market ? Sansrosa seems like such a cute name, it will be hard to pass up. Having said that though, it doesn’t sound like a typical prescription product name, so perhaps something more befitting of $150+ a month is required.

Related Articles:

• COL-118 (sansrosa) confirmed Phase 2 in 2007
• Sansrosa’s sister to enter redness race 
• sansrosa started as eye drops ?

How about you. Do you like what you see on the sample before and after photographs for Sansrosa ? Would you be willing to pay $150 a month (or more) ?